AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
09 Sep 2021 04:00 PM
RNS
Imfinzi improves survival in NSCLC in POSEIDON
09 Sep 2021 07:00 AM
RNS
PT027 PhIII asthma trials met primary endpoints
03 Sep 2021 07:00 AM
RNS
Ultomiris approved in EU for children with PNH
01 Sep 2021 03:00 PM
RNS
Total Voting Rights
26 Aug 2021 07:05 AM
RNS
Forxiga approved in Japan for CKD
26 Aug 2021 07:00 AM
RNS
ALXN1840 Wilson Phase III met primary endpoint
20 Aug 2021 07:05 AM
RNS
Update on Ultomiris Phase III ALS trial
20 Aug 2021 07:00 AM
RNS
AZD7442 prophylaxis trial met primary endpoint
16 Aug 2021 03:00 PM
RNS
Director/PDMR Shareholding
11 Aug 2021 02:35 PM
RNS
Update on US review of roxadustat
09 Aug 2021 07:05 AM
RNS
Forxiga approved in the EU for CKD
09 Aug 2021 07:00 AM
RNS
Enhertu head-to-head trial meets primary endpoint
02 Aug 2021 03:00 PM
RNS
Total Voting Rights
02 Aug 2021 07:00 AM
RNS
Saphnelo approved in the US for SLE
29 Jul 2021 07:00 AM
RNS
AZN: H1 2021 Results
26 Jul 2021 07:00 AM
RNS
Ultomiris recommended in EU for children with PNH
22 Jul 2021 07:00 AM
RNS
Directorate Change
21 Jul 2021 03:56 PM
RNS
Director/PDMR Shareholding
21 Jul 2021 03:45 PM
RNS
Total Voting Rights
21 Jul 2021 01:45 PM
RNS
Acquisition of Alexion completed
19 Jul 2021 07:00 AM
RNS
Imfinzi approved in China for extensive-stage SCLC
16 Jul 2021 07:00 AM
RNS
Status on US FDA Advisory Committee for roxadustat
14 Jul 2021 07:08 AM
RNS
AstraZeneca-Alexion transaction cleared in the UK
08 Jul 2021 07:00 AM
RNS
Tezepelumab granted FDA Priority Review for asthma
06 Jul 2021 07:00 AM
RNS
AstraZeneca-Alexion transaction cleared in the EU
01 Jul 2021 03:00 PM
RNS
Total Voting Rights
28 Jun 2021 07:05 AM
RNS
Forxiga recommended in EU for patients with CKD
28 Jun 2021 07:00 AM
RNS
Nirsevimab PhII/III trial confirms safety profile
24 Jun 2021 07:00 AM
RNS
Lynparza approved in China for prostate cancer
23 Jun 2021 07:00 AM
RNS
Orpathys approved in China for lung cancer
22 Jun 2021 07:00 AM
RNS
Koselugo approved in the EU for children with NF1
15 Jun 2021 07:00 AM
RNS
Update on AZD7442 STORM CHASER trial
07 Jun 2021 07:00 AM
RNS
Calquence head-to-head results versus ibrutinib
04 Jun 2021 07:05 AM
RNS
Lynparza reduced recurrence risk in breast cancer
04 Jun 2021 07:00 AM
RNS
AstraZeneca appoints new Chief Financial Officer
02 Jun 2021 07:00 AM
RNS
Publication of Final Terms
01 Jun 2021 03:01 PM
RNS
Block listing Interim Review
01 Jun 2021 03:00 PM
RNS
Total Voting Rights
28 May 2021 07:00 AM
RNS
Tagrisso approved in EU in early lung cancer
27 May 2021 04:41 PM
RNS
Second Price Monitoring Extn
27 May 2021 04:36 PM
RNS
Price Monitoring Extension
27 May 2021 07:00 AM
RNS
AstraZeneca prices a EUR800m bond offering
26 May 2021 07:00 AM
RNS
AstraZeneca prices a $7bn bond offering
25 May 2021 07:00 AM
RNS
EMTN programme update - publication of Prospectus
21 May 2021 07:00 AM
RNS
Vaxzevria COVID-19 vaccine approved in Japan
18 May 2021 03:30 PM
RNS
Director/PDMR Shareholding
11 May 2021 02:00 PM
RNS
Result of AGM
11 May 2021 01:55 PM
RNS
Shareholders vote in favour of Alexion acquisition
07 May 2021 07:00 AM
RNS
Imfinzi + tremelimumab showed survival in POSEIDON
04 May 2021 03:00 PM
RNS
Total Voting Rights
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100

Latest directors dealings